Atypical Gyrate Atrophy of Retina and Iminoglycinuria TAKASHI SAITO

Total Page:16

File Type:pdf, Size:1020Kb

Atypical Gyrate Atrophy of Retina and Iminoglycinuria TAKASHI SAITO Tohoku J. exp. Med., 1981, 135, 331-332 Short Report Atypical Gyrate Atrophy of the Choroid and Retina and Iminoglycinuria TAKASHI SAITO, SEIJI HAYASAKA,*KAZUYUKI YABATA,* KIYOSHIOMURA, KATSUYOSHI MIZUNO* and KEIYA TADA Departments of Pediatrics and *ophthalmology, Tohoku University School of Medicine, Sendai 980 SAITO, T., HAYASAKA, S., YABATA, K., OMURA, K., MIzuwo, K. and TADA, K. Atypical Gyrate Atrophy of the Choroid and Retina and Iminoglycinuria. Tohoku J. exp. Med., 1981, 135 (3), 331-332 A 44-year-old woman with atypical gyrate atrophy and iminoglycinuria was described. The serum ornithine level and ornithine-ketoacid transaminase (OKT) activity were both normal. Urinary excretion of proline, hydroxyproline and glycine was markedly increased. This finding, together with the existence of gyrate atrophy with hyperornithinemia due to OKT deficiency, suggests that proline deficiency in the chorioretinal tissues may concern the development of gyrate atrophy. - chorioretinal atrophy; hyperornithinemia; iminoglycinuria; proline Gyrate atrophy is a rare, inherited disease of chorioretinal atrophy. The plasma level of ornithine was found to be increased in affected patients (Simell and Takki 1973), and OKT in cultured skin fibroblasts was deficient in these patients. However, the mechanism of the ocular disturbance is still obscure because other patients with a similar degree of hyperornithinemia have no ocular problems (Gatfield et al. 1975) and there are cases of gyrate atrophy without hyperornithinemia (Jaeger et al. 1979). Recently we had a peculiar case which showed fundus changes similar to gyrate atrophy but lacked hyperornithinemia and in which urinary concentrations of imino- acids and glycine were markedly increased. PATIENT AND METHODS The patient was a 44-year-old woman whose parents were first cousins, and had a 5-year history of night blindness. She was referred to our University Hospital because of progressive visual disturbances. Ophthalmologic examination revealed myopia, dark blindness, constricted visual fields and chorioretinal atrophy in both eyes. Characteristic lesions resembling gyrate atrophy were noted at the lower periphery (Fig. 1). Serum and urinary amino acid levels were measured on a Hitachi amino acid analyzer (type 835). OKT activity in cultured skin fibroblasts was determined by spectrophoto- metric methods (Katsunuma et al. 1964). RESULTS AND DISCUSSION All of the routine laboratory tests showed normal values. The serum ornithine level was 1.51 mg/100 ml (normal 0.36-1.56 mg/100 ml) and other serum amino acid levels were also within normal range. OKT activity in cultured skin fibroblasts was 178 nmoles/mg protein/hr (normal controls: 182±8 nmoles/mg protein/hr). Received for publication, March 12, 1981. 331 332 T. Saito et al. Fig. 1. Ophthalmoscopic finding of the patient. TABLE 1. Endogeneous renal clearance of amino acids Amino acid analysis of urine showed a marked increase in iminoacids and glycine excretion; excreted proline content was 108 mg/day, hydroxyproline 36 mg/day and glycine 581 mg/day (Table 1). Iminoglycinuria (prolinuria) is known to be due to a defect in transport of iminoacids and glycine in the renal tubule (Tada et al. 1965). A large amount of proline is excreted in the urine in affected patients. In the patients with typical gyrate atrophy and hyperornithinemia, ornithine catabolism to proline is disturbed due to the deficiency of OKT. These observations suggest that a deficiency of proline in the chorioretinal tissues may concern the development of gyrate atrophy. References 1) Gatfield, P.D., Taller, E., Wolfe, D.M. & Haust, M.D. (1975) Hyperornithinernia, hyperammonemia and homocitrullinuria associated with decreased carbamyl phosphate synthetase I activity. Pediat. Res., 9, 488-497. 2) Jaeger, W., Kettler, J.V., Luty, P. & Hilsdorf, C. (1979) Differential diagnosis of gyrate atrophy of the choroid and retina. Metab. Pediat. Ophthal., 3, 189-191. 3) Katsunuma, N., Matsuda, Y. & Tomino, I. (1964) Studies on ornithine-ketoacid tran saminase. J. Biochem., 56, 499-503. 4) Simell, 0. & Takki, K. (1973) Raised plasma-ornithine and gyrate atrophy of the choroid and retina. Lancet, 1, 1031-1033. 5 ) Tada, K., Morikawa, T., Ando, T., Yoshida, T. & Minagawa , A. (1965) A new tubular defect in transport of proline and glycine. T ohoku J. exp . Med., 87, 133-143..
Recommended publications
  • Hyperammonemia in Review: Pathophysiology, Diagnosis, and Treatment
    Pediatr Nephrol DOI 10.1007/s00467-011-1838-5 EDUCATIONAL REVIEW Hyperammonemia in review: pathophysiology, diagnosis, and treatment Ari Auron & Patrick D. Brophy Received: 23 September 2010 /Revised: 9 January 2011 /Accepted: 12 January 2011 # IPNA 2011 Abstract Ammonia is an important source of nitrogen and is the breakdown and catabolism of dietary and bodily proteins, required for amino acid synthesis. It is also necessary for respectively. In healthy individuals, amino acids that are not normal acid-base balance. When present in high concentra- needed for protein synthesis are metabolized in various tions, ammonia is toxic. Endogenous ammonia intoxication chemical pathways, with the rest of the nitrogen waste being can occur when there is impaired capacity of the body to converted to urea. Ammonia is important for normal animal excrete nitrogenous waste, as seen with congenital enzymatic acid-base balance. During exercise, ammonia is produced in deficiencies. A variety of environmental causes and medica- skeletal muscle from deamination of adenosine monophos- tions may also lead to ammonia toxicity. Hyperammonemia phate and amino acid catabolism. In the brain, the latter refers to a clinical condition associated with elevated processes plus the activity of glutamate dehydrogenase ammonia levels manifested by a variety of symptoms and mediate ammonia production. After formation of ammonium signs, including significant central nervous system (CNS) from glutamine, α-ketoglutarate, a byproduct, may be abnormalities. Appropriate and timely management requires a degraded to produce two molecules of bicarbonate, which solid understanding of the fundamental pathophysiology, are then available to buffer acids produced by dietary sources. differential diagnosis, and treatment approaches available.
    [Show full text]
  • Effect of Propionic Acid on Fatty Acid Oxidation and U Reagenesis
    Pediat. Res. 10: 683- 686 (1976) Fatty degeneration propionic acid hyperammonemia propionic acidemia liver ureagenesls Effect of Propionic Acid on Fatty Acid Oxidation and U reagenesis ALLEN M. GLASGOW(23) AND H. PET ER C HASE UniversilY of Colorado Medical Celller, B. F. SlOlillsky LaboralOries , Denver, Colorado, USA Extract phosphate-buffered salin e, harvested with a brief treatment wi th tryps in- EDTA, washed twice with ph os ph ate-buffered saline, and Propionic acid significantly inhibited "CO z production from then suspended in ph os ph ate-buffe red saline (145 m M N a, 4.15 [I-"ejpalmitate at a concentration of 10 11 M in control fibroblasts m M K, 140 m M c/, 9.36 m M PO" pH 7.4) . I n mos t cases the cells and 100 11M in methyl malonic fibroblasts. This inhibition was we re incubated in 3 ml phosph ate-bu ffered sa lin e cont aining 0.5 similar to that produced by 4-pentenoic acid. Methylmalonic acid I1Ci ll-I4Cj palm it ate (19), final concentration approximately 3 11M also inhibited ' 'C0 2 production from [V 'ejpalmitate, but only at a added in 10 II I hexane. Increasing the amount of hexane to 100 II I concentration of I mM in control cells and 5 mM in methyl malonic did not impair palmit ate ox id ation. In two experiments (Fig. 3) the cells. fibroblasts were in cub ated in 3 ml calcium-free Krebs-Ringer Propionic acid (5 mM) also inhibited ureagenesis in rat liver phosphate buffer (2) co nt ain in g 5 g/ 100 ml essent iall y fatty ac id slices when ammonia was the substrate but not with aspartate and free bovine se rum albumin (20), I mM pa lm itate, and the same citrulline as substrates.
    [Show full text]
  • Propionic Acidemia Information for Health Professionals
    Propionic Acidemia Information for Health Professionals Propionic acidemia is an organic acid disorder in which individuals are lacking or have reduced activity of the enzyme propionyl-CoA carboxylase, leading to propionic acidemia. Clinical Symptoms Symptoms generally begin in the first few days following birth. Metabolic crisis can occur, particularly after fasting, periods of illness/infection, high protein intake, or during periods of stress on the body. Symptoms of a metabolic crisis include lethargy, behavior changes, feeding problems, hypotonia, and vomiting. If untreated, metabolic crises can lead to tachypnea, brain swelling, cardiomyopathy, seizures, coma, basal ganglia stroke, and death. Many babies die within the first year of life. Lab findings during a metabolic crisis commonly include urine ketones, hyperammonemia, metabolic acidosis, low platelets, low white blood cells, and high blood ammonia and glycine levels. Long term effects may occur despite treatment and include developmental delay, brain damage, dystonia, failure to thrive, short stature, spasticity, pancreatitis, osteoporosis, and skin lesions. Incidence Propionic acidemia occurs in greater than 1 in 75,000 live births and is more common in Saudi Arabians and the Inuit population of Greenland. Genetics of propionic acidemia Mutations in the PCCA and PCCB genes cause propionic acidemia. Mutations prevent the production of or reduce the activity of propionyl-CoA carboxylase, which converts propionyl-CoA to methylmalonyl-CoA. This causes the body to be unable to correctly process isoleucine, valine, methionine, and threonine, resulting in an accumulation of glycine and propionic acid, which causes the symptoms seen in this condition. How do people inherit propionic acidemia? Propionic acidemia is inherited in an autosomal recessive manner.
    [Show full text]
  • Arginine-Provider-Fact-Sheet.Pdf
    Arginine (Urea Cycle Disorder) Screening Fact Sheet for Health Care Providers Newborn Screening Program of the Oklahoma State Department of Health What is the differential diagnosis? Argininemia (arginase deficiency, hyperargininemia) What are the characteristics of argininemia? Disorders of arginine metabolism are included in a larger group of disorders, known as urea cycle disorders. Argininemia is an autosomal recessive inborn error of metabolism caused by a defect in the final step in the urea cycle. Most infants are born to parents who are both unknowingly asymptomatic carriers and have NO known history of a urea cycle disorder in their family. The incidence of all urea cycle disorders is estimated to be about 1:8,000 live births. The true incidence of argininemia is not known, but has been estimated between 1:350,000 and 1:1,000,000. Argininemia is usually asymptomatic in the neonatal period, although it can present with mild to moderate hyperammonemia. Untreated, argininemia usually progresses to severe spasticity, loss of ambulation, severe cognitive and intellectual disabilities and seizures Lifelong treatment includes a special diet, and special care during times of illness or stress. What is the screening methodology for argininemia? 1. An amino acid profile by Tandem Mass Spectrometry (MS/MS) is performed on each filter paper. 2. Arginine is the primary analyte. What is an in-range (normal) screen result for arginine? Arginine less than 100 mol/L is NOT consistent with argininemia. See Table 1. TABLE 1. In-range Arginine Newborn Screening Results What is an out-of-range (abnormal) screen for arginine? Arginine > 100 mol/L requires further testing.
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • The Pharmabiotic for Phenylketonuria: Development of a Novel Therapeutic
    University of South Carolina Scholar Commons Senior Theses Honors College Spring 2019 The hP armabiotic for Phenylketonuria: Development of a Novel Therapeutic Chloé Elizabeth LeBegue University of South Carolina, [email protected] Follow this and additional works at: https://scholarcommons.sc.edu/senior_theses Part of the Alternative and Complementary Medicine Commons, Amino Acids, Peptides, and Proteins Commons, Biochemical Phenomena, Metabolism, and Nutrition Commons, Biotechnology Commons, Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Digestive, Oral, and Skin Physiology Commons, Digestive System Diseases Commons, Enzymes and Coenzymes Commons, Genetic Phenomena Commons, Medical Biotechnology Commons, Medical Genetics Commons, Medical Nutrition Commons, Medical Pharmacology Commons, Nutritional and Metabolic Diseases Commons, Other Pharmacy and Pharmaceutical Sciences Commons, Pharmaceutical Preparations Commons, Pharmaceutics and Drug Design Commons, and the Preventive Medicine Commons Recommended Citation LeBegue, Chloé Elizabeth, "The hP armabiotic for Phenylketonuria: Development of a Novel Therapeutic" (2019). Senior Theses. 267. https://scholarcommons.sc.edu/senior_theses/267 This Thesis is brought to you by the Honors College at Scholar Commons. It has been accepted for inclusion in Senior Theses by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. THE PHARMABIOTIC FOR PHENYLKETONURIA: DEVELOPMENT OF A NOVEL THERAPEUTIC By Chloé Elizabeth
    [Show full text]
  • Fatal Propionic Acidemia: a Challenging Diagnosis
    Issue: Ir Med J; Vol 112; No. 7; P980 Fatal Propionic Acidemia: A Challenging Diagnosis A. Fulmali, N. Goggin 1. Department of Paediatrics, NDDH, Barnstaple, UK 2. Department of Paediatrics, UHW, Waterford, Ireland Dear Sir, We present a two days old neonate with severe form of propionic acidemia with lethal outcome. Propionic acidemia is an AR disorder, presents in the early neonatal period with progressive encephalopathy and death can occur quickly. A term neonate admitted to NICU on day 2 with poor feeding, lethargy and dehydration. Parents are non- consanguineous and there was no significant family history. Prenatal care had been excellent. Delivery had been uneventful. No resuscitation required with good APGAR scores. Baby had poor suck, lethargy, hypotonia and had lost about 13% of the birth weight. Initial investigations showed hypoglycemia (2.3mmol/L), uremia (8.3mmol/L), hypernatremia (149 mmol/L), severe metabolic acidosis (pH 7.24, HCO3 9.5, BE -18.9) with high anion gap (41) and ketonuria (4+). Hematologic parameters, inflammatory markers and CSF examination were unremarkable. Baby received initial fluid resuscitation and commenced on IV antibiotics. Generalised seizures became eminent at 70 hours of age. Loading doses of phenobarbitone and phenytoin were given. Hepatomegaly of 4cm was spotted on day 4 of life. Very soon baby became encephalopathic requiring invasive ventilation. At this stage clinical features were concerning for metabolic disorder and hence was transferred to tertiary care centre where further investigations showed high ammonia level (1178 μg/dl) and urinary organic acids were suggestive of propionic acidemia. Specific treatment for hyperammonemia and propionic acidemia was started.
    [Show full text]
  • Hyperglycinuria: a Family Report
    Nagoya J. Med. Sci. 42. 7 - 12, 1979 7 HYPERGLYCINURIA: A FAMILY REPORT TOMOAKI KATO Department ofPediatrics, Chubu-Rosai Hospital, Nagoya, Japan ABSTRACT A 3-year-old girl with mental retardation and a cleft palate disclosed hyperglycinuria. Serum glycine concentration was within the normal limits and renal clearance of glycine was elevated. Oral loading test of glycine showed that the intestinal absorption of glycine seemed to be nonnal. With intravenous loading of glycine, maximum tubular reabsorption rate (Tm) for glycine could not be obtained. Intravenous infusion of L-proline indicated that the Tm for proline was about half the normal value and that the impaired glycine reabsorption was further depressed. The patient's mother also had a reduced Tm for proline although she did not exhibit distinct hyperglycinuria. It seems likely that the patient and her mother have a heterozygous trait for iminoglycinuria. INTRODUCTION Hyperglycinuria is a rare hereditary disorder characterized by an excessive urinary excretion of glycine. It is caused by an impairment of glycine transport in the renal tubule. The hyperexcretion of glycine was first described in 1957 by de Vries et al. (5) in a family where four members exhibited hyperglycinuria, three of whom had renal stones of calcium oxalate. Hyperglycinuria has been reported at times in association with glucosuria (7), pancreatitis (I), cataract (14), hypophophatemic rickets (4, 12), or mercury intoxication (3). Isolated hyperglycinuria is also seen in heterozygotes with one form of iminoglycinuria (9) where homozygotes excrete excessive amounts of proline, hydroxyproline and glycine in the urine but heterozygotes exhibit a hyperexcretion of glycine only.
    [Show full text]
  • European Conference on Rare Diseases
    EUROPEAN CONFERENCE ON RARE DISEASES Luxembourg 21-22 June 2005 EUROPEAN CONFERENCE ON RARE DISEASES Copyright 2005 © Eurordis For more information: www.eurordis.org Webcast of the conference and abstracts: www.rare-luxembourg2005.org TABLE OF CONTENT_3 ------------------------------------------------- ACKNOWLEDGEMENTS AND CREDITS A specialised clinic for Rare Diseases : the RD TABLE OF CONTENTS Outpatient’s Clinic (RDOC) in Italy …………… 48 ------------------------------------------------- ------------------------------------------------- 4 / RARE, BUT EXISTING The organisers particularly wish to thank ACKNOWLEDGEMENTS AND CREDITS 4.1 No code, no name, no existence …………… 49 ------------------------------------------------- the following persons/organisations/companies 4.2 Why do we need to code rare diseases? … 50 PROGRAMME COMMITTEE for their role : ------------------------------------------------- Members of the Programme Committee ……… 6 5 / RESEARCH AND CARE Conference Programme …………………………… 7 …… HER ROYAL HIGHNESS THE GRAND DUCHESS OF LUXEMBOURG Key features of the conference …………………… 12 5.1 Research for Rare Diseases in the EU 54 • Participants ……………………………………… 12 5.2 Fighting the fragmentation of research …… 55 A multi-disciplinary approach ………………… 55 THE EUROPEAN COMMISSION Funding of the conference ……………………… 14 Transfer of academic research towards • ------------------------------------------------- industrial development ………………………… 60 THE GOVERNEMENT OF LUXEMBOURG Speakers ……………………………………………… 16 Strengthening cooperation between academia
    [Show full text]
  • Screening for Inherited Metabolic Disease in Wales Using Urine-Impregnated Filter Paper
    Arch Dis Child: first published as 10.1136/adc.50.4.264 on 1 April 1975. Downloaded from Archives of Disease in Childhood, 1975, 50, 264. Screening for inherited metabolic disease in Wales using urine-impregnated filter paper D. M. BRADLEY From the Department of Medicine, Welsh National School of Medicine, Heath Park, Cardiff Bradley, D. M. (1975). Archives of Disease in Childhood, 50, 264. Screening for inherited metabolic disease in Wales using urine-impregnated filter paper. Urine specimens from 135 295 infants have been collected on filter paper and tested for 7 abnormal urinary constituents using spot tests and paper chromato- graphy. The method has detected 5 infants with phenylketonuria, 4 with histidinae- mia, 5 with cystinuria, 5 with diabetes mellitus, and one with alcaptonuria. Transient abnormalities such as tyrosyluria, generalized aminoaciduria, cystinuria, and glyco- suria have been noted. 2 phenylketonuric infants failed to excrete a detectable quantity of o-hydroxyphenylacetic acid at the time of testing. The findings show that the detection of this compound in urine is an unreliable method of screening for phenylketonuria. Early detection of phenylketonuria became Method essential when it was found that the severe mental Collection of urine specimens. The recom- retardation associated with this disorder could be mended time of testing is between the 10th and 14th prevented by introducing a low phenylalanine diet day of life. In practice, 53% of all specimens are in the first months of life (Bickel, Gerrard, and collected by the 14th day, rising to 98% by the 28th Hickmans, 1953). The Medical Research Council day (Table I).
    [Show full text]
  • Laboratory Diagnostic Approaches in Metabolic Disorders
    470 Review Article on Inborn Errors of Metabolism Page 1 of 14 Laboratory diagnostic approaches in metabolic disorders Ruben Bonilla Guerrero1, Denise Salazar2, Pranoot Tanpaiboon2,3 1Formerly Quest Diagnostics, Inc., Ruben Bonilla Guerrero, Rancho Santa Margarita, CA, USA; 2Quest Diagnostics, Inc., Denise Salazar and Pranoot Tanpaiboon, San Juan Capistrano, CA, USA; 3Genetics and Metabolism, Children’s National Rare Disease Institute, Washington, DC, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: R Bonilla Guerrero; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Ruben Bonilla Guerrero. Formerly Quest Diagnostics, Inc., Ruben Bonilla Guerrero, 508 Sable, Rancho Santa Margarita, CA 92688, USA. Email: [email protected]. Abstract: The diagnosis of inborn errors of metabolism (IEM) takes many forms. Due to the implementation and advances in newborn screening (NBS), the diagnosis of many IEM has become relatively easy utilizing laboratory biomarkers. For the majority of IEM, early diagnosis prevents the onset of severe clinical symptoms, thus reducing morbidity and mortality. However, due to molecular, biochemical, and clinical variability of IEM, not all disorders included in NBS programs will be detected and diagnosed by screening alone. This article provides a general overview and simplified guidelines for the diagnosis of IEM in patients with and without an acute metabolic decompensation, with early or late onset of clinical symptoms. The proper use of routine laboratory results in the initial patient assessment is also discussed, which can help guide efficient ordering of specialized laboratory tests to confirm a potential diagnosis and initiate treatment as soon as possible.
    [Show full text]
  • Blueprint Genetics Hyperammonemia and Urea Cycle Disorder Panel
    Hyperammonemia and Urea Cycle Disorder Panel Test code: ME1601 Is a 49 gene panel that includes assessment of non-coding variants. Is ideal for patients with hyperammonemia or a clinical suspicion of a disorder of urea cycle metabolism. The genes on this panel are included in the Comprehensive Metabolism Panel. About Hyperammonemia and Urea Cycle Disorder Congenital urea cycle disorders are the result of defects in the metabolism of nitrogen waste. Deficiency of any of the enzymes in the urea cycle results in an excess of ammonia or other precursor metabolites in the blood. Normally, urea production lowers the ammonia levels in the blood but in the case of defective enzymes, the urea cycle is disturbed. Infants with urea cycle disorders (UCDs) develop cerebral edema, lethargy, hypothermia, neurologic signs and coma, often shortly after birth. Partial, or milder, UCDs are possible if the affected enzyme is positioned in a later phase of the urea cycle. Patients with UCDs may present with hyperammonemia often triggered by stress or illness. The most common primary hyperammonemia is X-linked recessive ornithine transcarbamylase deficiency caused by mutations in the OTC gene. The estimated prevalence is 1:56,000. Prevalence estimates for the other specific urea cycle disorders are 1:200,000 for ASL- and ASS1-related deficiencies and <1:1,000,000 for ARG1, CPS1 and NAGS-related deficiencies. The diagnostic yield ranges from 50% to 80% for different primary urea cycle disorders. In addition to congenital UCDs, this panel has the ability to diagnose other diseases of early phase hyperammonemia and other inborn errors of metabolism showing similar and overlapping symptoms.
    [Show full text]